Skip to main content

Q-DAPSA for Measuring Disease Activity in PsA

Given its multiple domains, there remains much discussion over the best disease activity scoring method in PsA. The proverbial "holy grail" would be a measure that is quick, intuitive, domain comprehensive and validated.

Poster POS1069 evaluated the Q-DAPSA for disease activity in PsA. The DAPSA, a validated uni-dimensional, joint specific calculation, with a quick quantitative C-reactive protein (qCRP) constitutes this measure. The elements of the DAPSA are highlighted in this graphic and available here as a PDF.   

Proft et al, evaluated 104 PsA patients between January and October 2020. The mean patient age was 51.2 years, mean disease duration of 7.1 years, and 47.1% of patients were male. Fifty one percent of the patients were treated with bDMARD and 37 patients were on csDMARDs. Mean CRP and qCRP values were 5.2mg/l and 6.17mg/l, respectively. One hundred and three patients (99%) were assigned to the same disease activity category based on comparison of their Q-DAPSA and DAPSA scores. 

Based on this small study, it appears the Q-DAPSA (DAPSA plus qCRP) may prove to be an efficient and effective disease activity measure in PsA that is relevant from research, clinical, and treat-to-target perspectives. 

Some limitations include the small population but also the difficulty with the DAPSA in accounting for different domains.


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.